Rxivist logo

The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high dose challenge, resulting in strongly reduced viral infection and replication in upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic. ### Competing Interest Statement N.P.K. is a co-founder, shareholder, and chair of the scientific advisory board of Icosavax, Inc. All other authors declare no competing interests.

Download data

  • Downloaded 720 times
  • Download rankings, all-time:
    • Site-wide: 38,283
    • In immunology: 1,182
  • Year to date:
    • Site-wide: 20,524
  • Since beginning of last month:
    • Site-wide: 28,047

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide